Dimdazenil: Difference between revisions
CSV import |
CSV import |
||
| Line 3: | Line 3: | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = 477318123 | | verifiedrevid = 477318123 | ||
| IUPAC_name = 8-Chloro-11-(2-chlorophenyl)-6,11-dihydro-5H- | | IUPAC_name = 8-Chloro-11-(2-chlorophenyl)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepin-5-one | ||
| image = Dimdazenil.svg | | image = Dimdazenil.svg | ||
| image_size = 200px | | image_size = 200px | ||
| image_alt = Chemical structure of Dimdazenil | | image_alt = Chemical structure of Dimdazenil | ||
| image_caption = Chemical structure of Dimdazenil | |||
}} | }} | ||
'''Dimdazenil''' is a | '''Dimdazenil''' is a [[benzodiazepine]] derivative that has been studied for its potential use as an [[anxiolytic]] and [[anticonvulsant]] agent. It is a partial agonist at the [[benzodiazepine receptor]] site on the [[GABA_A receptor]], which is the primary inhibitory neurotransmitter receptor in the [[central nervous system]]. | ||
[[ | |||
==Pharmacology== | ==Pharmacology== | ||
Dimdazenil acts | Dimdazenil acts as a partial agonist at the benzodiazepine site of the GABA<sub>A</sub> receptor. This action enhances the effect of the neurotransmitter [[gamma-aminobutyric acid]] (GABA) at this receptor, leading to increased [[neuronal inhibition]] and producing [[sedative]], [[anxiolytic]], and [[anticonvulsant]] effects. Unlike full agonists, partial agonists like dimdazenil may produce fewer side effects such as [[sedation]] and [[muscle relaxation]], making them potentially useful in clinical settings where these effects are undesirable. | ||
== | ==Clinical Use== | ||
While dimdazenil has shown promise in preclinical studies, it is not currently approved for clinical use. Research has focused on its potential to treat [[anxiety disorders]] and [[epilepsy]], but further studies are needed to fully understand its efficacy and safety profile. | |||
== | ==Chemical Properties== | ||
Dimdazenil | Dimdazenil is chemically classified as a benzodiazepine derivative. Its chemical structure includes a [[chlorine]] atom at the 8-position and a 2-chlorophenyl group, which are believed to contribute to its pharmacological activity. The presence of these groups may influence its binding affinity and selectivity for the benzodiazepine receptor. | ||
== | ==Synthesis== | ||
The synthesis of dimdazenil involves the formation of the imidazo[2,1-b][3]benzazepin-5-one core structure, followed by the introduction of the chloro substituents. The specific synthetic route can vary, but typically involves multi-step organic synthesis techniques common in the production of benzodiazepine derivatives. | |||
== | ==Potential Advantages== | ||
As | As a partial agonist, dimdazenil may offer advantages over traditional benzodiazepines, such as a lower risk of [[tolerance]] and [[dependence]]. This could make it a safer alternative for long-term use in treating chronic conditions like anxiety and epilepsy. | ||
==Related Pages== | ==Related Pages== | ||
* [[Benzodiazepine]] | * [[Benzodiazepine]] | ||
* [[GABA_A receptor]] | |||
* [[Anxiolytic]] | * [[Anxiolytic]] | ||
* [[Anticonvulsant]] | * [[Anticonvulsant]] | ||
[[Category:Benzodiazepines]] | [[Category:Benzodiazepines]] | ||
[[Category:Anxiolytics]] | [[Category:Anxiolytics]] | ||
[[Category:Anticonvulsants]] | [[Category:Anticonvulsants]] | ||
Latest revision as of 23:27, 5 March 2025
A benzodiazepine derivative
| Dimdazenil | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Dimdazenil is a benzodiazepine derivative that has been studied for its potential use as an anxiolytic and anticonvulsant agent. It is a partial agonist at the benzodiazepine receptor site on the GABA_A receptor, which is the primary inhibitory neurotransmitter receptor in the central nervous system.
Pharmacology[edit]
Dimdazenil acts as a partial agonist at the benzodiazepine site of the GABAA receptor. This action enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at this receptor, leading to increased neuronal inhibition and producing sedative, anxiolytic, and anticonvulsant effects. Unlike full agonists, partial agonists like dimdazenil may produce fewer side effects such as sedation and muscle relaxation, making them potentially useful in clinical settings where these effects are undesirable.
Clinical Use[edit]
While dimdazenil has shown promise in preclinical studies, it is not currently approved for clinical use. Research has focused on its potential to treat anxiety disorders and epilepsy, but further studies are needed to fully understand its efficacy and safety profile.
Chemical Properties[edit]
Dimdazenil is chemically classified as a benzodiazepine derivative. Its chemical structure includes a chlorine atom at the 8-position and a 2-chlorophenyl group, which are believed to contribute to its pharmacological activity. The presence of these groups may influence its binding affinity and selectivity for the benzodiazepine receptor.
Synthesis[edit]
The synthesis of dimdazenil involves the formation of the imidazo[2,1-b][3]benzazepin-5-one core structure, followed by the introduction of the chloro substituents. The specific synthetic route can vary, but typically involves multi-step organic synthesis techniques common in the production of benzodiazepine derivatives.
Potential Advantages[edit]
As a partial agonist, dimdazenil may offer advantages over traditional benzodiazepines, such as a lower risk of tolerance and dependence. This could make it a safer alternative for long-term use in treating chronic conditions like anxiety and epilepsy.
